May 25, 2020
Bayer said on May 22 that it has filed a new drug application in Japan for its site-agnostic cancer drug larotrectinib for the treatment of neurotrophic tyrosine receptor kinase (NTRK) fusion gene positive locally advanced/metastatic solid tumors. Bayer licensed larotrectinib,...read more